FluMist® is now TGA-registered in Australia for the prevention of influenza in children and adolescents aged 2 to <18 years, offering a needle-free vaccination option ahead of the 2026 flu season. International experience, including in the UK and Finland, shows that intranasal vaccination can improve uptake in younger age groups who may be averse to needles. Current evidence indicates FluMist® is as effective as traditional intramuscular influenza vaccines.
Administration requirements
FluMist® must be administered by a health professional. Pharmacists are required to ensure accurate do…
